An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

Journal:

Nature Medicine

Published:

2026-01-16

DOI:

10.1038/s41591-025-04169-6

Affiliations:

8

Authors:

16

Go to article

Institutions	Authors	Share
OrsoBio, Inc., United States of America (USA)	8.000000	0.50
Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland	4.000000	0.25
Cincinnati Children's Hospital Medical Center (CCHMC), United States of America (USA)	1.666667	0.10
WM Therapeutics (WMT), Germany	1.000000	0.06
New Zealand Clinical Research (NZCR), New Zealand	0.500000	0.03
The University of Auckland, New Zealand	0.500000	0.03
WPI Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), UOsaka, Japan	0.333333	0.02

Interested in Cardiovascular Medicine and Haematology?